AKR1C3

1RY0, 1RY8, 1S1P, 1S1R, 1S2A, 1S2C, 1XF0, 1ZQ5, 2F38, 2FGB, 3R43, 3R58, 3R6I, 3R7M, 3R8G, 3R8H, 3R94, 3UFY, 3UG8, 3UGR, 3UWE, 4DBS, 4DBU, 4DBW, 4DZ5, 4FA3, 4FAL, 4FAM, 4H7C, 4HMN, 4WDT, 4WDU, 4WDW, 4WDX, 4WRH, 4XVD, 4XVE, 4ZFC, 4YVX, 4YVV8644105349ENSG00000196139ENSMUSG00000021214P42330Q8K023NM_003739NM_001253908NM_001253909NM_016253NM_134066NM_001346535NP_001240837NP_001240838NP_003730NP_001333464NP_598827Aldo-keto reductase family 1 member C3 (AKR1C3), also known as 17β-hydroxysteroid dehydrogenase type 5 (17β-HSD5, HSD17B5) or 3α-hydroxysteroid dehydrogenase type 2 (3α-HSD2)[5][6][7] is a steroidogenic enzyme that in humans is encoded by the AKR1C3 gene.

[8][9][10] This gene encodes a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins.

These enzymes catalyze the conversion of aldehydes and ketones to their corresponding alcohols by utilizing NADH and/or NADPH as cofactors.

The enzymes display overlapping but distinct substrate specificity.

In addition, AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression.